Monitor the upcoming shareholder vote on preferred stock conversion; approval would restore equity compliance and remove near-term delisting risk, while denial could trigger redemption demands and accelerate delisting. Given the $6M market cap, any adverse development could be severely dilutive or wipe out equity.
Price Chart
Executive Summary
Transcode Therapeutics received a Nasdaq deficiency notice for failing to meet the $2.5M minimum stockholders' equity requirement, reporting equity of only $1.25M as of March 31, 2026. The company is soliciting shareholder approval to convert Series A and B preferred stock into common stock to boost equity and regain compliance, but failure could lead to redemption demands and potential delisting.
Key Financial Metrics
Key Facts
- Received Nasdaq deficiency letter on May 19, 2026, for non-compliance with Listing Rule 5550(b)(1) (minimum stockholders' equity of $2.5M)
- Stockholders' equity as of March 31, 2026, was $1,251,427, well below the $2.5M threshold
- Company must submit a compliance plan by July 3, 2026, and may get up to 180 days extension
- Seeking shareholder approval to convert Series A and B preferred stock into common stock to reclassify as equity and regain compliance
- If approval not obtained by Dec 31, 2026, preferred holders can demand redemption at fair value, creating cash outflow risk
Financial Impact
Stockholders' equity deficiency of $1,248,573 relative to $2.5M requirement; potential cash redemption of Series A preferred if conversion not approved
Risk Factors
- Shareholder vote may fail to approve conversion, leading to preferred redemption demands and potential cash crunch
- Nasdaq may reject the compliance plan or fail to grant an extension, resulting in delisting
- Even if compliance plan is accepted, the company may not regain compliance within extension period
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001104659-26-065966 |
| Document: 0001104659-26-065966-index-headers.html | 0001104659-26-065966 |
| Document: 0001104659-26-065966-index.html | 0001104659-26-065966 |
| Document: 0001104659-26-065966.txt | 0001104659-26-065966 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 28, 2026 28d ago | 8-K | $1.71 $1.71 | ▼ −0.26% | ▼ −0.23% | $1.71 (−0.23%) |
Sep 21, 2026 5w ago | 3 | $1.77 $1.68 | ▼ −5.08% | ▼ −4.52% | $1.71 (−3.62%) |
Sep 11, 2026 6w ago | 8-K | $1.65 $1.63 | ▲ +1.21% | ▲ +3.48% | $1.71 (−3.39%) |
Jul 2, 2026 16w ago | 8-K | $8.61 $4.22 | ▼ −50.99% | ▼ −51.84% | $1.71 (−80.19%) |
Jun 18, 2026 18w ago | 8-K | $4.70 $8.27 | ▲ +75.96% | ▲ +75.42% | $1.71 (−63.70%) |
Jun 3, 2026 20w ago | 8-K | $5.04 $8.61 | ▲ +70.83% | ▲ +71.83% | $1.71 (−66.15%) |
May 26, 2026 21w ago | DEFA14A | $5.39 $4.94 | ▲ +8.35% | ▲ +6.40% | $1.71 (+68.35%) |
Apr 30, 2026 25w ago | S-3 | $7.83 $5.44 | ▲ +30.59% | ▲ +35.85% | $1.71 (+78.21%) |
Apr 7, 2026 28w ago | 8-K | $8.70 $7.74 | ▲ +11.03% | ▲ +20.82% | $1.71 (+80.39%) |
Mar 3, 2026 33w ago | DEFA14A | $9.84 $8.69 | ▼ −11.69% | ▼ −7.27% | $1.71 (−82.66%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers